Fundraising FoxAditum Bio — Full Portfolio
11 tracked investments · listed companies and verified rows first
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Eli LillyDavid A. Ricks(Chair, President, and Chief Executive Officer)Lucas Montarce(Executive Vice President and Chief Financial Officer)inDaniel M. Skovronsky(Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs)in
Co-investorsKleiner PerkinsMassChallenge MexicoMicron Ventures
Coastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis.
BiotechHealthtechMedical DevicesOakland, US
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical DevicesOakland, US
Donald Ganem(Executive Officer, Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Co-investorsPMV
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion.
BiotechHealthtechMedical DevicesLexington, US
Samantha Truex(Chief Executive Officer)in
Co-investorsGV (Google Ventures)
Trames Bio is a biotech company developing gene therapies for chronic neuropathic pain, using chemogenetics to deliver an AAV-encoded inhibitory ion channel to specific pain neurons that is then activated by an oral small molecule for on-demand, reversible nerve block.
AI & Machine LearningBiotechDeep Tech
Co-investorsTCG CrossoverAtlas Venture
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Tempero Bio, Inc.VersanisVitalli Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.